AI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for RVMD.
Price change · trailing returns
Live · FMP| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.84% | +2.85% | +9.27% | +54.36% | +102.52% | +97.72% | +287.40% | +531.69% | +421.11% | +444.91% | +444.91% |
Aftermarket
Live · FMPLast trade
$158.04
248 sh
Bid
$153.11
1 sh
Ask
$158.61
2 sh
Spread
$5.500
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $159.00 (+0.97%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancerglobenewswire.com·May 06, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progressglobenewswire.com·May 06, 2026
- US FDA authorizes early access to Revolution's pancreatic cancer pillreuters.com·May 01, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|